Drotaverine

Small moleculeexperimental

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
1

Earliest trial started May 1, 2005 (NCT00292747)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC
Mol. weight
397.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-benzyl-3',4',6,7-tetraethoxy-1,2,3,4- tetrahydroisoquinoline
  • dihydroethaverine
  • dihydroethaverine
  • dihydroisoperparine
  • dihydroisoperparine
  • dihydroisoperparine
  • dihydroisoperparine
  • dihydroisoperparine
  • dihydroisoperparine
  • drotaverin
  • drotaverin
  • drotaverin
  • drotaverin
  • drotaverine
  • drotaverine
  • drotaverine
  • drotaverine
  • drotaverine
  • drotaverine
  • drotaverine
  • drotaverine hcl
  • drotaverine hydrochloride
  • drotaverine hydrochloride
  • drotaverine hydrochloride
  • drotaverin hydrochloride
  • drotaverin hydrochloride
  • drotin
  • drotin
  • isodihydroperparine
  • isodihydroperparine
  • no-shpa
  • no-spa
  • nospan
  • nospanum

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01639027Phase 2/Phase 3 (Phase 3)May 1, 2012Ain Shams University
NCT01236651Phase 2Nov 1, 2010Ain Shams University
NCT00731198Phase 3Aug 1, 2008Changhai Hospital
NCT00292747Phase 4May 1, 2005Sanofi, Sanofi-Aventis
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ain Shams UniversityAcademic/Hospital2222010
Changhai HospitalAcademic/Hospital1112008
SanofiFor profit1112005
Sanofi-AventisFor profit1012005
4 organizations
Page 1 / 1